This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Asia: Oligonucleotide & Peptide Therapeutics Scientific Forum
See You Next Year! 26-28 Feb, 2025
Westin Miyako KyotoKyoto, Japan

Henrik Oerum, PhD
Founder and Chief Scientific Officer at CiVi Biopharma Inc.


Dr. Ørum, brings more than 20 years of experience in every aspect of creating, building, leading and exiting successful Biotech companies.

He holds an M.Sc. in genetic engineering from the University of Natural Sciences in Copenhagen and a Ph.D in molecular biology from the Medical University of Copenhagen. Following his PhD, he did a Post.Doc at the Pharmaceutical University. He is the author of more than 70 peer reviewed publications and numerous patent applications.

Dr. Ørum started his biotech career as CSO at PNA Diagnostics A/S, where he worked from 1993 to 1999. During his tenure the company was sold to Boehringer Mannheim in 1994 and later to Hoffman-La Roche in 1997. In 1996, he cofounded Exiqon A/S, a nucleic acid diagnostics company that was floated on the Copenhagen Stock Exchange in 2007 (CSE:EXQ). In 2000 he co-founded Santaris Pharma A/S, where he served as CSO and VP of Business Development until the acquisition by Roche in 2014. Following the acquisition, Dr. Ørum worked for Roche Pharma as Global Head of RNA therapeutics until 2016, where he left to pursue new opportunities, that eventually led him to found CiVi Biopharma inc.

Agenda Sessions

  • CIVI 008: An Orally Active LNA Drug Against PCSK9